Spero Financial Statements From 2010 to 2025

Spero Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 120.1 M 110.5 M 78 M Slightly volatile Other Current Liabilities 11.2 M 17.7 M 8.5 M Slightly volatile Total Current Liabilities 51.5 M 49.1 M 17.8 M Slightly volatile Total Stockholder Equity 80.9 M 46.1 M 51.1 M Slightly volatile Other Liabilities 26.9 M 25.6 M 10.2 M Slightly volatile Property Plant And Equipment Net 4.7 M 3.1 M 3.3 M Slightly volatile Current Deferred Revenue 349.6 K 368 K 3.3 M Slightly volatile Accounts Payable 7.7 M 7.3 M 2.6 M Slightly volatile Cash 66.4 M 52.9 M 43.6 M Slightly volatile Non Current Assets Total 3.1 M 3.3 M 10.4 M Slightly volatile Non Currrent Assets Other 145.3 K 153 K 7.2 M Slightly volatile Other Assets 1.09 1.15 1.5 M Slightly volatile Cash And Short Term Investments 89.4 M 52.9 M 58.1 M Slightly volatile Net Receivables 55.1 M 52.5 M 11.3 M Slightly volatile Common Stock Shares Outstanding 27.3 M 54 M 19.3 M Slightly volatile Liabilities And Stockholders Equity 120.1 M 110.5 M 78 M Slightly volatile Non Current Liabilities Total 17.6 M 15.3 M 11.4 M Slightly volatile Other Current Assets 1.8 M 1.9 M 4.5 M Slightly volatile Other Stockholder Equity 337.5 M 505.7 M 212.9 M Slightly volatile Total Liabilities 39.7 M 64.4 M 27.4 M Slightly volatile Deferred Long Term Liabilities 262.9 K 363.4 K 216.8 K Slightly volatile Property Plant And Equipment Gross 6.2 M 6.7 M 4.2 M Slightly volatile Total Current Assets 102.9 M 107.3 M 66.7 M Slightly volatile Short Term Debt 2 M 3.5 M 1.4 M Slightly volatile Property Plant Equipment 3.9 M 6.3 M 3.1 M Slightly volatile Non Current Liabilities Other 95 K 100 K 7 M Very volatile Common Stock 52.2 K 55 K 3.5 M Slightly volatile Noncontrolling Interest In Consolidated Entity 284 K 319.5 K 348.3 K Slightly volatile Common Stock Total Equity 21.7 K 33.4 K 19.9 K Slightly volatile Capital Surpluse 307.8 M 471.2 M 274.8 M Slightly volatile Additional Paid In Capital 145.1 M 163.3 M 178 M Slightly volatile Net Invested Capital 72.4 M 46.1 M 86.8 M Very volatile Net Working Capital 77.3 M 58.2 M 89.8 M Pretty Stable Capital Stock 41.3 K 55 K 27.5 K Slightly volatile Short and Long Term Debt Total 5 M 4.3 M 5.8 M Very volatile Long Term Debt Total 170.4 K 159.3 K 220.5 K Slightly volatile Capital Lease Obligations 5 M 4.3 M 5.8 M Very volatile
Spero Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 1.9 K 2 K 353.9 K Slightly volatile Selling General Administrative 21.7 M 23.7 M 14.4 M Slightly volatile Other Operating Expenses 71.4 M 100.8 M 49.2 M Slightly volatile Research Development 54.7 M 96.8 M 38 M Slightly volatile Cost Of Revenue 1.9 K 2 K 14.3 M Pretty Stable Total Operating Expenses 71.4 M 100.8 M 49.2 M Slightly volatile Preferred Stock And Other Adjustments 4.9 M 5.5 M 6 M Slightly volatile Reconciled Depreciation 1.9 K 2 K 419.4 K Very volatile Non Operating Income Net Other 1.2 M 749.7 K 1.5 M Slightly volatile Selling And Marketing Expenses 452.8 K 509.4 K 555.4 K Slightly volatile
Spero Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Sale Purchase Of Stock 8.8 M 9.3 M 25.8 M Very volatile Stock Based Compensation 5.2 M 7.8 M 3.3 M Slightly volatile Begin Period Cash Flow 60.6 M 76.3 M 38.3 M Slightly volatile Depreciation 1.9 K 2 K 282.1 K Slightly volatile End Period Cash Flow 66.4 M 52.9 M 43.6 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 1.93 2.0316 109 Slightly volatile Dividend Yield 0.0031 0.0035 0.0038 Slightly volatile PTB Ratio 1.15 1.2068 147 Slightly volatile Days Sales Outstanding 734 699 348 Pretty Stable Stock Based Compensation To Revenue 0.53 0.2845 0.506 Slightly volatile Capex To Depreciation 0.066 0.0694 8.5308 Slightly volatile PB Ratio 1.15 1.2068 147 Slightly volatile Payables Turnover 3.0E-4 3.0E-4 7.4809 Pretty Stable Sales General And Administrative To Revenue 0.82 0.8652 10.6391 Slightly volatile Research And Ddevelopement To Revenue 3.36 3.5318 38.024 Slightly volatile Capex To Revenue 0.0023 0.0025 1.1291 Slightly volatile Cash Per Share 0.93 0.9787 4.3046 Very volatile Days Payables Outstanding 1.5 K 1.6 K 22.6 K Slightly volatile Current Ratio 2.08 2.186 3.7877 Slightly volatile Receivables Turnover 0.5 0.5221 4.2603 Pretty Stable Shareholders Equity Per Share 0.81 0.8535 3.7734 Very volatile Debt To Equity 0.0599 0.0932 0.0737 Very volatile Capex Per Share 0.0014 0.0015 0.0331 Slightly volatile Revenue Per Share 0.53 0.507 0.4251 Slightly volatile Interest Debt Per Share 0.0755 0.0795 0.1511 Pretty Stable Debt To Assets 0.0493 0.0389 0.0493 Slightly volatile Graham Number 3.55 4.0 4.3602 Slightly volatile Price Book Value Ratio 1.15 1.2068 147 Slightly volatile Days Of Payables Outstanding 1.5 K 1.6 K 22.6 K Slightly volatile Ebt Per Ebit 0.82 0.9346 0.9996 Very volatile Company Equity Multiplier 2.28 2.3967 14.7369 Slightly volatile Total Debt To Capitalization 0.0556 0.0852 0.0685 Very volatile Debt Equity Ratio 0.0599 0.0932 0.0737 Very volatile Quick Ratio 2.08 2.186 3.9663 Slightly volatile Net Income Per E B T 0.74 0.81 0.8666 Slightly volatile Cash Ratio 1.02 1.0777 2.6597 Pretty Stable Days Of Sales Outstanding 734 699 348 Pretty Stable Free Cash Flow Operating Cash Flow Ratio 1.12 1.15 1.032 Slightly volatile Price To Book Ratio 1.15 1.2068 147 Slightly volatile Fixed Asset Turnover 9.24 8.7977 3.6831 Slightly volatile Debt Ratio 0.0493 0.0389 0.0493 Slightly volatile Price Sales Ratio 1.93 2.0316 109 Slightly volatile Asset Turnover 0.13 0.2478 0.1082 Slightly volatile Price Fair Value 1.15 1.2068 147 Slightly volatile
Spero Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 52.9 M 55.7 M 125.9 M Pretty Stable

Spero Fundamental Market Drivers

Spero Upcoming Events

About Spero Therapeutics Financial Statements

Pair Trading with Spero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:

How To Invest In Spero Details

Is Spero Stock a good investment? Details

What is Spero Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details